GSK lightens portfolio, shrinks footprint

Share this article:
GSK lightens porfolio, shrinks footprint
GSK lightens porfolio, shrinks footprint

GlaxoSmithKline is selling thrombosis meds Arixtra and Fraxiparine to the Aspen Group, a longtime partner in GSK's ongoing effort to transfer drugs from its books to another entity. The company said in a statement Monday that the deal will include $1.3 million in cash and that it transfers global rights, with few exceptions, to the products and to a manufacturing site (the Notre Dame de Bondeville site) and “certain dedicated commercial employees.” GSK said in a statement that the deal “is a further example of GSK's commitment to increase focus on products with the most growth potential.”

Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.